Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer
#anti-CD3 (Biogems, USA) ; #anti-CD28 (Biogems, USA) ; #BioGems International ; Cancer Cell Int 24, 225 (2024). Cancer Cell International volume 24, Article number: 225 (2024) Cite this article Abstract Background Despite the improved survival observed in PD-1/PD-L1 blockade therapy, a substantial proportion of cancer patients, including those with non-small cell lung cancer (NSCLC), still lack a response. Methods Transcriptomic profiling …